Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.
New COVID-19 vaccine candidates proved safe with no serious side effects and generated immune responses comparable to existing vaccines.
We conducted a phase 2, randomized, active-controlled, observer-blind study (NCT05960097) among healthy adults ≥18 y of age who completed a primary COVID-19 mRNA vaccination series, with or without a booster, ≥3 months e... No serious side effects were considered related to the investigational vaccines, and no deaths occurred.All but the lowest dose of the second investigational vaccine induced immune responses that were comparable to the a...
What the study was
- Study design
- Randomized study
- Sample size
- 425
- Category
- Other
- Maturity
- Exploratory
- Journal
- Human vaccines & immunotherapeutics
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Sentinel'. Components — novelty:1/3, relevance:2/3, design:2/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.